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Abstract
Purpose—To assess acute and late adverse events (AEs), overall survival (OS), pelvic failure 
(PF), regional failure, distant failure, and disease-free survival (DFS) in a prospective phase II 
clinical trial of bevacizumab (Bev) and pelvic intensity modulated radiation therapy (IMRT) with 
chemotherapy in high-risk endometrial-cancer patients.
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Materials/Methods—Patients had a hysterectomy, lymph node removal, and ≥1 of the 
following high-risk factors: grade 3 carcinoma with >50% myometrial invasion; grade 2 or 3 
disease with any cervical stromal invasion; or known extrauterine extension confined to the pelvis. 
Treatment included pelvic IMRT and concurrent cisplatin on days 1 and 29 of radiation and Bev 
(5 mg/kg on days 1, 15 and 29 of radiation) followed by adjuvant carboplatin and paclitaxel for 4 
cycles. The primary endpoint was grade ≥3 AEs in the first 90 days.
Results—Thirty-four patients were accrued from November 2009 through December 2011, 30 of 
whom were eligible and received study treatment. Seven out of 30 patients (23.3%, 90% CI: 
10.6%-36.0%) had grade ≥3 treatment-related non-hematologic toxicities within 90 days; an 
additional 6 patients had grade ≥3 toxicities between 90 and 365 days after treatment. Two-year 
OS was 96.7% and DFS was 79.1%. No patient developed a within-field PF and no patients with 
stage I-IIIA disease relapsed after a median follow-up of 26 months.
Conclusion—Postoperative Bev added to chemotherapy and pelvic IMRT is well tolerated and 
results in high overall survival rates at 2 years for patients with high-risk endometrial carcinoma.
INTRODUCTION
Endometrial cancer is the most common cancer of the female reproductive organs in the 
United States. Over 50,000 women are diagnosed annually, with the majority presenting 
with early-stage disease curable by surgery alone.1 Nevertheless, more than 8,000 women 
die of the disease each year due to a combination of local and distant failures.1 Prior studies 
have indicated that pelvic external beam radiation may reduce the risk of local recurrence in 
high-risk patients, while chemotherapy may decrease the risk of distant metastasis. In the 
Gynecologic Oncology Group (GOG) randomized trial, chemotherapy was associated with 
reduced distant metastases (22 vs. 18%) in stage III/IV patients,2 but not in stage I/II 
patients.3 The Radiation Therapy Oncology Group (RTOG) 9708 phase II clinical trial 
treated women with high-risk endometrial cancer with pelvic radiation and concurrent 
cisplatin, followed by additional cisplatin and paclitaxel chemotherapy. Results showed a 
low rate of local recurrence (2%), but a high rate of distant metastases (19%).4 Given these 
and other findings, it was postulated that the addition of bevacizumab (Bev), an anti-
angiogenic agent, may further reduce the risk of distant metastases. With prior trials 
demonstrating the feasibility of using pelvic intensity modulated radiation therapy (IMRT) 
in postoperative patients,5 IMRT was chosen in the hope of reducing the incidence or 
severity of bowel toxicity, which might be exacerbated by Bev.
The primary objective of this trial was to assess the rates of grade ≥3, non-hematologic, 
treatment-related adverse events (AEs) within 90 days from the start of treatment when 
administering concurrent Bev, cisplatin, and IMRT followed by carboplatin and paclitaxel 
chemotherapy in patients with high-risk endometrial cancer. The secondary objectives were 
to evaluate treatment-related AEs occurring within one year from start of treatment; all 
treatment-related AEs; disease-free and overall survival (DFS, OS); and local, regional and 
distant failure. Two-year efficacy rates are reported.
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Eligibility requirements for RTOG 0921
A hysterectomy and bilateral salpingo-oophorectomy must have been completed within 56 
days prior to study entry with pathologic confirmation of uterine cancer meeting one or 
more of the following criteria: grade 3 carcinoma with >50% myometrial invasion (all 
papillary serous and clear cell carcinomas were considered grade 3); grade 2 or 3 carcinoma 
with any cervical stromal invasion; or known extra-uterine disease confined to the pelvis, 
any grade. The following histologies were allowed: endometrioid endometrial 
adenocarcinoma, clear cell carcinoma, papillary serous adenocarcinoma, adenosquamous 
carcinoma or other adenocarcinoma variant. All patients had Zubrod performance status 0-1, 
were ≥18 years of age, and were able to sign a study-specific informed consent. Patients 
must have had adequate bone marrow, renal and hepatic function as indicated by the 
following laboratory assessments within 21 days prior to study entry: ANC ≥1500 cells/mm3 
without use of growth factors; platelets ≥100,000/mm3; serum creatinine ≤1.5 mg/dl; total 
bilirubin ≤1.5 times institutional upper normal limit; hemoglobin ≥10 g/dl (transfusion may 
have been used to meet this criterion); AST and ALT ≤2 times institutional upper normal 
limit; INR <1.5 for patients treated with warfarin within 14 days prior to study entry; urine 
protein creatinine (UPC) ratio (if UPC ratio >0.5, 24-hour urine protein should be obtained 
and should be <1000 mg for patient enrollment) ; in patients with FIGO stage III or IVA 
disease, CT or PET-CT of the abdomen and pelvis was required within 56 days of study 
entry. To assess the chest for all patients regardless of stage, a chest x-ray or chest CT or 
PET-CT was required within 56 days of study entry.
Treatment
No sooner than 29 days and no later than 56 days after surgery, patients began a course of 
IMRT with concurrent cisplatin (50 mg/m2 on days 1 and 29 of radiation) and Bev (5 mg/kg 
on days 1, 15 and 29 of radiation) followed by an optional boost with either high-dose-rate 
(HDR, 6 Gy for 3 fractions) or low-dose-rate (LDR, 25 Gy at 0.8-1.2 Gy per hour) vaginal 
brachytherapy. This was followed by 4 cycles of carboplatin (AUC 5) and paclitaxel (135 
mg/m2).
Full- and empty-bladder CT scans were required and were fused together prior to outlining 
target volumes. Contours were recommended to follow the RTOG IMRT for postoperative 
endometrial and cervical cancer guideline atlas6 and underwent central review with 
corrections recommended prior to initiating treatment.
The vaginal planning target volume (PTV) (integrated target volume with a 7-mm margin) 
and nodal PTV (nodal CTV with a 7-mm margin) were prescribed 45 Gy in 25 fractions. 
The dose was prescribed to cover 97% of the vaginal PTV and nodal PTV. Bone-marrow 
sparing with IMRT was not required and no bone dose-volume constraints were 
implemented as part of this protocol. Patients with pelvic lymph node(s) ≥2 cm in any 
dimension on the diagnostic or planning CT or biopsy-proven to be positive were candidates 
to receive, at the discretion of the treating radiation oncologist, 8 additional fractions to the 
enlarged node(s) in 1.8-Gy daily fractions for a total dose of 59.4 Gy to the nodal boost 
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PTV. Patients were followed for disease status with history and physical examination every 
3 months for 1 year, every 6 months for another 2 years, and annually thereafter.
Statistical analysis
Primary endpoint—Given that the rate of acute grade ≥3 non-hematologic treatment-
related AEs from RTOG 9708 (RT + cisplatin) was 44%, the hypothesis for the current trial 
was that the addition of Bev to IMRT + cisplatin would not increase this rate beyond 60%. 
This study was designed with a 1-sided, upper-bound confidence interval to estimate this AE 
rate. Twenty-seven evaluable patients were required to have 95% confidence that the true 
grade ≥3, non-hematologic, treatment-related AE rate is not greater than 60%. To allow for 
ineligible/non-protocol treatment patients, a total sample size of 34 patients was required for 
this study. AEs were scored according to the National Cancer Institute Common 
Terminology Criteria for AEs, version 4.0 (MedDRA version 12.0).
Secondary endpoints—For overall survival (OS), failure was defined as death due to 
any cause and survival time was measured from date of study entry to death or last follow-
up for non-failures. Data for living patients were censored at the date of last contact. Pelvic 
failure (PF) was defined as recurrence in the pelvis, including the pelvic or sacral nodes, and 
required confirmation by histologic or cytologic biopsy of the recurrent lesion. Regional 
failure (RF) was defined as recurrence in the para-aortic nodal region. Distant failure (DF) 
was defined as the appearance of distant metastasis. Death was considered a competing risk 
for PF, RF, and DF and each were measured from date of study entry to date of first failure 
or last follow-up for non-failures. For disease-free survival (DFS), failure was defined as PF, 
DF, or death due to any cause and was measured from date of study entry to date of first 
failure or last follow-up for non-failures. OS and DFS were estimated univariately with the 
Kaplan-Meier method7 and PF, RF, and DF rates were estimated using the cumulative 
incidence method.8
RESULTS
A total of 34 patients were accrued from November 6, 2009 until December 12, 2011. Four 
patients were excluded from analysis: 1 did not receive protocol treatment and 3 were 
ineligible (1 had a PET/CT scan >56 days prior to study registration, 1 had positive 
peritoneal cytology, and 1 had urinary protein creatinine >1). Detailed baseline patient 
characteristics of the 30 patients included in the analysis are listed in Table 1. A total of 29 
of 30 patients underwent bilateral pelvic lymph node dissection and 19 had para-aortic 
lymph node removal.
Protocol Treatment Compliance
A total of 93% of patients were treated per protocol with concurrent chemotherapy and 90% 
received their adjuvant chemotherapy per protocol. All patients received Bev in full and on 
time.
Radiation treatment compliance was assessed in terms of whether physician contours of the 
tumor volume and organs at risk, which underwent rapid review within 24 hours, followed 
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the protocol-recommended contouring guidelines. For tumor-volume contouring, 23 were 
per protocol and 7 (23%) had an acceptable variation.
For organs-at-risk contouring, 27 patients were considered per protocol while 3 (10%) had 
acceptable variations. Bladder, sigmoid, femur and tumor volume were all contoured per 
protocol on final submission (after rapid review for institutional first case). Barium contrast 
given by mouth to opacify the small bowel was allowed at the physician's discretion. Two 
patients (6.7%) had unacceptable deviations on small-bowel contouring, where the bowel 
loops were contoured instead of the bowel space; in the other 28 cases, the small bowel was 
contoured per protocol. One patient had an acceptable variation on rectum contouring, with 
the inferior portion of the rectal contour overlapping the vaginal integrated target volume 
(ITV); the other 29 rectal contours were per protocol.
Compliance was also assessed with regard to treatment planning, with assessments of 
whether the nodal and vaginal PTV, bladder, rectum, femoral heads and bowel planned 
doses met the protocol set dose limits. With regard to treatment planning, 5 cases had 
‘deviation unacceptable’ (>0.03 cc of PTV receiving <91% of prescription) and 12 had 
‘variation acceptable’ (>0.03 cc of PTV receiving 91-93% of prescription) scores for the 
tumor dose-volume analysis, due to the minimum dose requirements. For normal tissues, 
only one ‘deviation unacceptable’ was recorded for small bowel and no ‘deviation 
unacceptable’ cases were noted for bladder, rectum or femoral heads, though 12 patients had 
acceptable variations for the dose-volume analysis recorded (Table 2).
Primary Endpoint
Acute Adverse Events—Of the 30 patients, 7 (23.3%, 95% CI: 10.6%-36.0%) developed 
grade ≥3, treatment-related, non-hematologic AEs ≤90 days from the start of concurrent 
treatment (i.e., acute AEs). Table 3a lists the grade 3 and 4 side effects, including 
hematologic toxicity, in detail. As the one-sided, upper-bound confidence interval for the 
rate of grade ≥3, treatment-related, nonhematologic AEs occurring ≤90 days from the start 
of concurrent treatment is 36%, there is 95% confidence that the true grade ≥3, non-
hematologic, treatment-related AE rate is not greater than 60%. One acute toxicity, a 
thromboembolic event, was considered possibly attributable to Bev.
Secondary Endpoints
Late Adverse Events—Treatment-related grade ≥3 AEs occurring >90 days but ≤365 
days from the start of concurrent treatment are listed in Table 3b. Nine patients reported late 
AEs, three of whom also had acute toxicities.
AEs occurring during concurrent treatment, adjuvant chemotherapy treatment, and after the 
end of all treatment are shown in Table 4. One late toxicity, epistaxis, was considered 
possibly attributable to Bev.
Survival outcomes—The median follow-up time for all patients was 25.9 months (min-
max: 13.6-43.4). The 2-year estimate of OS was 96.7% (95% CI: 78.6%-99.5%) with a total 
of 4 deaths, all from endometrial cancer. None of the 30 patients enrolled had a within-field 
pelvic-only failure. The cumulative incidences for RF and DF at 2 years were 7.2% (95% 
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CI: 0.0%-17.1%) and 17% (95% CI: 3.2%-30.9%), respectively. The 2-year estimate of DFS 
was 79.1% (95% CI: 59.2%-90.1%). A total of 6 patients had recurrent disease. Two of the 6 
had para-aortic nodal failures; one of these also had distant-nodal metastases, and both 
subsequently died. One of the two patients with para-aortic nodal failure had undergone a 
para-aortic lymph node dissection at diagnosis; both had undergone pelvic node 
lymphadenectomy at diagnosis. Two of the other four patients died of distant disease. The 
remaining two patients were alive with distant failure at the time of this analysis; one 
remains on chemotherapy and the other had a 1-cm recurrence in the peritoneum above the 
pelvic field at a laparoscopic port site, which was resected laparoscopically with negative 
margins. She remains on megestrol acetate and has been disease free for 2 years. Detailed 
characteristics of the patients with recurrence are shown in Table 5.
DISCUSSION
This phase II prospective trial demonstrates the feasibility of administering bevacizumab 
(Bev) with pelvic intensity modulated radiation therapy (IMRT) followed by carboplatin/
paclitaxel chemotherapy in high-risk endometrial cancer. The rate of acute grade >3, non-
hematologic, treatment-related toxicity was 23.3% and the hypothesis that the true rate of 
such AEs is not greater than 60% was confirmed. This treatment regimen is feasible with 
few Bev-related toxicities. A total of 93% of patients were treated per protocol with 
concurrent chemotherapy and 90% received their adjuvant chemotherapy per protocol. All 
patients received Bev in full and on time. Compared to RTOG 9708, changes in this trial 
include adding Bev to concurrent cisplatin-based chemoradiation, switching from cisplatin/
paclitaxel to carboplatin/paclitaxel after concurrent chemoradiation, and using IMRT instead 
of 3D conformal radiation.
In this RTOG 0921 trial of concurrent Bev, cisplatin and radiation, one acute toxicity, a 
thromboembolic event, and one late toxicity, epistaxis, were considered possibly attributable 
to Bev. Therefore, this study uniquely finds that Bev may be administered during pelvic 
radiation to the post-operative pelvis without increasing pelvic complications. There were no 
side effects attributable to the use of carboplatin instead of cisplatin in conjunction with 
paclitaxel. The use of adjuvant chemotherapy in comparison to radiation in high-
intermediate or advanced-stage endometrial-cancer patients has been reported in three 
randomized trials; none used carboplatin/paclitaxel.
Other studies have shown an effect of Bev in endometrial cancer. One study treated patients 
with recurrent disease definitively to a local field with concurrent radiation and Bev 10 
mg/m2 every 2 weeks for 3 doses; no other chemotherapy was administered.9 Results 
showed 2 out of 19 patients had thromboembolic events, 2 patients had grade 1 and 3 
patients had grade 2 proteinuria, 2 patients had grade 1 and 2 patients had grade 2 
hypertension, and 1 patient had a grade 1 nosebleed. Dramatic shrinkage of the tumor was 
noted for patients with recurrent endometrial cancer, with a 3-year overall survival rate of 
80%. Another study analyzed data from patients with persistent or recurrent endometrial 
cancer treated with Bev 15 mg/kg every 3 weeks until disease progression or prohibitive 
toxicity without other chemotherapy.10 The authors reported an overall response rate of 
13.5%, a median progression-free survival of 4 months and a median overall survival time 
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of 10 months. In comparison, in the current study, patients were treated immediately 
postoperatively rather than at the time of recurrence, and they received a dose of 5mg/kg in 
order to minimize side effects related to Bev.
Chemotherapy has been variously compared to radiation and combined with it. In trials 
comparing the two modalities, the chemotherapy-alone arms demonstrate local relapse rates 
of 18% for women with stage III-IV disease2 and 11%11 or 7%12 for those with stage IC-
IIIC disease. Chemotherapy is thought to confer a survival advantage when combined with 
radiation.13 For patients with high-intermediate and advanced disease, a combination of 
chemotherapy and radiation offers potential reductions in both local and distant relapses. 
The GOG 0184 trial randomized patients treated with surgery and pelvic and/or para-aortic 
radiation to cisplatin and doxorubicin with or without paclitaxel; 10% had a local-regional 
recurrence and 30% had distant recurrence.14 RTOG 9708, a phase II trial of concurrent 
cisplatin with radiation and 4 cycles of cisplatin (50 mg/m2) and paclitaxel (175 mg/m2 
every 4 weeks) after radiation, showed a 4-year pelvic recurrence rate of 2%, a regional 
recurrence rate of 2% and a distant recurrence rate of 19%.4 No recurrences occurred in the 
13 stage IC, IIA, or IIB patients.15 In terms of clinical outcomes, at 2 years, RTOG 9708 had 
a 2-year overall survival rate of 91% compared to this study at 97%, however continued 
follow-up is required for more complete conclusions. These studies indicate the efficacy of 
combined chemo-radiation at improving local control, but demonstrate the need for novel 
agents to reduce the rate of distant relapse. This trial was administered to patients with 
performance status 0-1; it is not clear whether patients with worse performance status would 
tolerate the addition of bevacizumab and chemotherapy.
IMRT treats regions at risk for disease spread while sparing adjacent normal tissues. IMRT 
may reduce the dose to normal tissues, thereby potentially decreasing acute and chronic 
toxicity.16,17 Retrospective studies of pelvic IMRT indicate that the volume of small bowel 
treated to more than 45 Gy is smaller with IMRT than with whole-pelvic radiation. 
Portelance et al. showed a >60% reduction in the volume of small bowel irradiated to more 
than 45 Gy with IMRT.18 A study by Roeske and colleagues showed a 50% reduction in the 
volume of small bowel irradiated to more than 45 Gy.19
Overall, the grade 3 or higher toxicity rate reported during concurrent treatment in RTOG 
9708 (3D conformal pelvic radiation and concurrent cisplatin chemotherapy followed by 
adjuvant cisplatin and paclitaxel) was 30%. To determine whether IMRT may be of benefit 
in reducing this rate, toxicities during radiation in the current study (RTOG 0921) were 
compared to those of the precursor trial RTOG 9708. In RTOG 9708, during the concurrent 
portion of the treatment, 43% of participants had grade 2, 27% had grade 3, and 2% had 
grade 4 acute toxicity; in this RTOG 0921 trial, these rates were 30%, 23% and 7%, 
respectively. Of note, though the systems are similar, toxicity in RTOG 9708 was assessed 
according to the Cooperative Group Common Toxicity Criteria 1989, the Acute Radiation 
Morbidity Scoring Criteria, and the Late Radiation Morbidity Scoring Scheme of the RTOG 
and the European Organization for Research and Treatment of Cancer, whereas the current 
trial used the subsequent CTCAE version 4.0 which developed from the preceding scales. 
Prospective results from the ongoing RTOG 1203 TIME-C randomized trial may help to 
clarify whether IMRT reduces toxicity compared to 3D conformal radiation.
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Relative to RTOG 0418, a prospective series of patients treated with postoperative pelvic 
IMRT, the less strict dose-volume histogram criteria used in the current trial resulted in 
higher compliance for constraints. In RTOG 0418, dose criteria were not met in 67% of 
cases for bladder, in 76% for rectum, and in 17% for small bowel. In comparison, in the 
current trial, dose criteria were not met in 14% (4/29) of cases for bladder, in 24% (7/29) for 
rectum, and in 14% (4/28) for bowel. To illustrate the effect of stringency, the femoral head 
constraint in RTOG 0921 was met in all cases (all had DVH value of 15% receiving < 35 
Gy); in contrast, the RTOG 0418 constraint was not met in 33% of cases (<15% of the 
femoral heads receiving ≥30 Gy). No increase in toxicity was noted with the less stringent 
constraints. The high number of variations in PTV calculations indicates the need for 
relaxation of these constraints in future trials.
In conclusion, treating endometrial-cancer patients with concurrent bevacizumab, cisplatin 
and pelvic radiation followed by carboplatin/paclitaxel chemotherapy is feasible, has low 
rates of bevacizumab-specific toxicities and a high survival rate at 2 years. Future 
randomized trials should further address the use of bevacizumab in endometrial cancer.
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    Median (min-max) 59 (34 – 80)
Hysterectomy procedure
    Robotic-assisted vaginal hysterectomy 30% (9)
    Total abdominal hysterectomy 23.3% (7)
    Radical hysterectomy 23.3% (7)
    Laparoscopic-assisted vaginal hysterectomy 23.3% (7)
Pelvic lymph node removal
    Yes 96.7% (29)
    No 3.3% (1)
Para-aortic lymph node removal
    Yes 63.3% (19)
    No 36.7% (11)
Histologic type
    Endometrioid endometrial adenocarcinoma 60% (18)
    Papillary serous adenocarcinoma 30% (9)
    Clear cell carcinoma 10% (3)
Stages
    Papillary serous or clear cell adenocarcinoma:
        I 16.7% (5)
        II 13.3% (4)
        IIIC1 10% (3)
    Endometrioid endometrial adenocarcinoma:
        II 6.7% (2)
        IIIA 16.7% (5)
        IIIB 3.3% (1)
        IIIC1 33.3% (10)
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Table 2
Tumor and Normal-Tissue Dose-Volume Analysis Criteria and Score Statistics
Structure Per Protocol Variation Acceptable Deviation Unacceptable
PTV ≥0.03 cc of PTV 
with ≥93% of 
prescribed dose
43% (13) ≥0.03 cc of PTV 
with 91-<93% of 
prescribed dose
40% (12) ≥0.03 cc of PTV with 
<91% of prescribed dose
17% (5)
Small bowel (missing, 
n=2)
30% receives <40 
Gy
86% (24) 30% receives >40-
<45 Gy
11% (3) >30% receives >45 Gy and 
≥0.03 cc .receives >65 Gy
4% (1)
Rectum (missing, n=1) 60% receives ≤40 
Gy
76% (22) 60% receives 40-< 
45 Gy
24% (7) >60% receives >45 Gy and 
≥0.03 cc receives >65 Gy
0% (0)
Bladder (missing, n=1) 35% receives ≤45 
Gy
86% (25) 35% receives 45-
<50 Gy
14% (4) >35% receives >50 Gy and 
≥0.03 cc receives >65 Gy
0% (0)
Femoral heads 15% receives <35 
Gy
100% (30) >15% - ≤50% 
receives >35 Gy
0% (0) >50% receives >35 Gy and 
≥0.03 cc receives >65 Gy
0% (0)
Key: Rx=prescription; Gy = Gray, PTV = planning target volume
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Table 3a
a. Adverse events ≥ grade 3 in the first 90 days from the start of concurrent treatment (acute)
System Organ Class Term Grade Relationship to Treatment Days from 
Concurrent RX 
start
Nervous system disorders Headache 3 Probable 78
General disorders and administration 
site conditions
Fatigue 3 Probable 85
Nervous system disorders Syncope 3 Possible 89
Vascular disorders Thromboembolic event* 4 Probable 42
Metabolism and nutrition disorders Hyponatremia 3 Probable 55
Hyperglycemia 3 Possible 90
Infections and infestations Vaginal infection 3 Probable 28
Reproductive system and breast 
disorders
Vaginal inflammation 3 Possible 27
Investigations Alanine aminotransferase increased 3 Possible 12
Blood and lymphatic system disorders Febrile neutropenia 4 Probable 88
General disorders and administration 
site conditions
Fatigue 3 Possible 4
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Table 3b
b. Adverse events ≥ grade 3 occurring >90 days but ≤365 from the start of concurrent treatment (late)
System Organ Class Term Grade Relationship to Treatment Days from Concurrent 
RX start
General disorders and administration site conditions Fatigue 3 Probable 105
Metabolism and nutrition disorders Hypomagnesemia 4 Possible 183
Hypokalemia 3 Possible 168
Respiratory, thoracic and mediastinal disorders Epistaxis* 3 Probable 176
Nervous system disorders Headache 3 Probable 98
Metabolism and nutrition disorders Hyponatremia 3 Possible 98
Vascular disorders Hot flashes 3 Definite 300
General disorders and administration site conditions Pain 3 Possible 180
Ear and labyrinth disorders Hearing impaired 3 Probable 333
Metabolism and nutrition disorders Hypokalemia 4 Probable 136
Nervous system disorders Neuralgia 3 Possible 126
Infections and infestations Skin infection 3 Possible 126
Key: RX=treatment
*probably attributable to bevacizumab
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Table 4
Summary of Worst Adverse Event per Patient (definitely, probably, or possibly related to treatment) 
comparing RTOG 9708 with RTOG 0921
Grade
AEs ≤90 days 
from the start 
of all RX1
AEs >90 days from the start of all 
RX2
AEs occurring during 
concurrent RX3
AEs occurring during adjuvant 
chemo4
RTOG 0921 RTOG 0921 RTOG 9708 RTOG 0921 RTOG 9708 RTOG 0921 RTOG 9708
1 0 ( 0%) 3 (10%) 9 (20%) 1 ( 3%) 12 (27%) 0 ( 0%) 3 ( 7%)
2 10 (33%) 10 (33%) 17 (39%) 9 (30%) 19 (43%) 6 (20%) 3 ( 7%)
3 11 (37%) 9 (30%) 7 (16%) 7 (23%) 12 (27%) 12 (40%) 9 (21%)
4 5 (17%) 6 (20%) 1 ( 2%) 2 ( 7%) 1 ( 2%) 6 (20%) 26 (62%)
5 0 ( 0%) 0 ( 0%) 0 ( 0%) 0 ( 0%) 0 ( 0%) 0 ( 0%) 0 ( 0%)
Key: RX=treatment
1AE date ≤ (start of all treatment +90 days)
2AE date > (start of all treatment +90 days)
3Concurrent treatment start date ≤ AE date ≤ concurrent treatment end date
4Adjuvant treatment start date ≤ AE date ≤ adjuvant treatment end date
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Table 5
Characteristics of patients with relapsed disease
Patient Stage Histology First recurrence Areas of spread Time from first recurrence to death (months)
1 IIIC1 UPSC Regional Para-aortic node 10
2 IIIC1 UPSC Regional Para-aortic node 4
3 IIIC1G2 EAC Distant Lung, bone, brain 8
4 IIIC1G3 EAC Distant Lung 6
5 IIIBG3 EAC Distant Lung Alive
6 IIIAG1 EAC Distant Abdominal Alive
Key: EAC= Endometrioid endometrial adenocarcinoma; CC=Clear cell carcinoma; UPSC=Papillary serous adenocarcinoma
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